Crispr Therapeutics shares tumble after significant earnings miss
LONDON - The Financial Conduct Authority (FCA) has announced the temporary suspension of daVictus Plc’s ordinary shares from the Official List, effective today at 7:30 AM. The suspension follows a request from the company itself and affects the equity shares listed under the ISIN JE00BYY5RQ34.
The ordinary shares in question fall under the listing category of equity shares (transition) and are fully paid with no par value. This suspension will remain in place until further notice, with no specific timeframe for when the shares might resume trading.
According to the FCA’s statement, the suspension is a regulatory measure, and the notice has been disseminated by Issuer Management, a division of the FCA responsible for overseeing the compliance of listed companies with listing rules.
Investors holding daVictus Plc shares will be unable to trade them on the London Stock Exchange (LON:LSEG), where they are normally admitted to trading, as well as on any other Recognised Investment Exchanges listed by the company until the suspension is lifted.
The FCA has not provided additional details regarding the reasons behind daVictus Plc’s request for suspension. It is standard practice for the FCA to issue notices concerning the admission and suspension of securities on the Official List in conjunction with notices from Recognised Investment Exchanges about trading on their markets.
The London Stock Exchange, where daVictus Plc’s securities are primarily traded, assigns SEDOL numbers as identifiers for securities, which can be found in their dealing notices. The suspension notice for daVictus Plc is based on a press release statement and has been circulated by RNS, the news service of the London Stock Exchange. RNS is authorized by the FCA to act as a Primary Information Provider in the United Kingdom (TADAWUL:4280).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.